Skip to main content

Table 2 Treatment-related NCI CTCAE Version 3.0 Grade 3 or 4 treatment-emergent adverse events

From: A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

System organ class, n (%) huKS-IL2 dosing cohort, mg/m2 Total (n = 27)
0.5 1.0 2.0 3.0 4.0
(n = 3) (n = 4) (n = 7) (n = 6) (n = 7)
Any treatment-related TEAE of NCI CTCAE Grade 3 or 4 2 (67) 0 2 (29) 2 (33) 5 (71) 11 (41)
Blood/lymphatic system disorders       
 Lymphopenia 1 (33) 0 1 (14) 2 (33) 1 (14) 5 (19)
 Anemia 0 0 0 0 1 (14) 1 (4)
 Neutropenia 0 0 0 0 1 (14) 1 (4)
 Thrombocytopenia 0 0 0 0 1 (14) 1 (4)
 WBC count decreased 0 0 0 0 1 (14) 1 (4)
Investigations       
 Blood phosphorus equivalents increased 0 0 0 0 1(14) 1 (4)
 GGT increased 0 0 0 1 (17) 0 1 (4)
Gastrointestinal disorders       
 Ascites 1 (33) 0 0 0 0 1 (4)
 Nausea 0 0 0 0 1 (14) 1 (4)
 Vomiting 0 0 0 0 1 (14) 1 (4)
Metabolism/nutrition disorders       
 Hypophosphatemia 0 0 1 (14) 0 1 (14) 2 (7)
Respiratory/thoracic/mediastinal disorders       
 Dyspnea 0 0 0 1 (17) 0 1 (4)
 Bronchospasm 0 0 0 1 (17) 0 1 (4)
 Hypoxia 0 0 1 (14) 0 0 1 (4)
  1. CTCAE, Common Terminology Criteria for Adverse Events; GGT, gamma-glutamyltransferase; huKS-IL2, humanized KS-interleukin-2; NCI, National Cancer Institute; TEAE, treatment-emergent adverse event; WBC, white blood cell.